Richard S.E. Keefe
Professor in Psychiatry and Behavioral Sciences
Education & Training
Ph.D., New York University 1990
Xavier, RM, Dungan, JR, Keefe, RSE, and Vorderstrasse, A. "Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia. (Accepted)" Schizophrenia research. Cognition 12 (June 2018): 11-19. Full Text
Kendler, KS, Ohlsson, H, Keefe, RSE, Sundquist, K, and Sundquist, J. "The joint impact of cognitive performance in adolescence and familial cognitive aptitude on risk for major psychiatric disorders: a delineation of four potential pathways to illness." Molecular psychiatry 23.4 (April 2018): 1076-1083. Full Text
Xavier, RM, Pan, W, Dungan, JR, Keefe, RSE, and Vorderstrasse, A. "Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia." Schizophrenia research 193 (March 2018): 83-90. Full Text
Hochberger, WC, Combs, T, Reilly, JL, Bishop, JR, Keefe, RSE, Clementz, BA, Keshavan, MS, Pearlson, GD, Tamminga, CA, Hill, SK, and Sweeney, JA. "Deviation from expected cognitive ability across psychotic disorders." Schizophrenia research 192 (February 2018): 300-307. Full Text
Ang, MS, Abdul Rashid, NA, Lam, M, Rapisarda, A, Kraus, M, Keefe, RSE, and Lee, J. "The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia." Journal of clinical psychopharmacology 37.6 (December 2017): 651-656. Full Text
Khan, A, Liharska, L, Harvey, PD, Atkins, A, Ulshen, D, and Keefe, RSE. "Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency." Innovations in clinical neuroscience 14.11-12 (December 2017): 30-40.
Harvey, PD, Khan, A, and Keefe, RSE. "Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience." Innovations in clinical neuroscience 14.11-12 (December 2017): 18-22.
Georgiades, A, Davis, VG, Atkins, AS, Khan, A, Walker, TW, Loebel, A, Haig, G, Hilt, DC, Dunayevich, E, Umbricht, D, Sand, M, and Keefe, RSE. "Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients." Schizophrenia research 190 (December 2017): 172-179. Full Text
Blokland, GAM, Del Re, EC, Mesholam-Gately, RI, Jovicich, J, Trampush, JW, Keshavan, MS, DeLisi, LE, Walters, JTR, Turner, JA, Malhotra, AK, Lencz, T, Shenton, ME, Voineskos, AN, Rujescu, D, Giegling, I, Kahn, RS, Roffman, JL, Holt, DJ, Ehrlich, S, Kikinis, Z, Dazzan, P, Murray, RM, Di Forti, M, Lee, J, Sim, K, Lam, M, Wolthusen, RPF, de Zwarte, SMC, Walton, E, Cosgrove, D, Kelly, S, Maleki, N, Osiecki, L, Picchioni, MM, Bramon, E, Russo, M, David, AS, Mondelli, V, Reinders, AATS, and Falcone, MA et al. "The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project." Schizophrenia research (October 2, 2017). Full Text
Vance, M, Pappadopulos, E, Keefe, R, and Kalali, A. "Conceptual issues in cultural adaptation and the role of culture in assessment of health-related quality of life in schizophrenia." Beyond Assessment of Quality of Life in Schizophrenia. January 1, 2016. 53-62. Full Text
Eum, S, Hill, SK, Rubin, LH, Carnahan, RM, Reilly, JL, Ivleva, EI, Keedy, SK, Tamminga, CA, Pearlson, GD, Clementz, BA, Gershon, ES, Keshavan, MS, Keefe, RSE, Sweeney, JA, and Bishop, JR. "Cognitive burden of anticholinergic medications in psychotic disorders." December 2017. Full Text
Graham, KA, Keefe, RS, Lieberman, JA, Calikoglu, AS, Lansing, KM, and Perkins, DO. "Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia." October 2015. Full Text
Keefe, R, Mahableshwarkar, A, and Olsen, C. "P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine." October 2013. Full Text
Madhoo, M, Roth, RM, Keefe, RSE, Sambunaris, A, Scheckner, B, Nielsen, J, Adeyi, B, Wu, J, and Lasser, R. "Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels." October 2012. Full Text
Madhoo, M, Keefe, RSE, Roth, RM, Sambunaris, A, Wu, J, Trivedi, MH, Anderson, CS, and Lasser, R. "Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder." June 2012.
Supina, D, Endicott, J, Madhoo, M, Keefe, RSE, Trivedi, M, Wu, J, Scheckner, B, and Lasser, R. "EFFECTS OF LISDEXAMFETAMINE DIMESYLATE AUGMENTATION ON FUNCTIONAL OUTCOMES IN ADULTS WITH PARTIALLY OR FULLY REMITTED MAJOR DEPRESSIVE DISORDER." June 2012. Full Text
Jarskog, FF, Grove, RA, McEvoy, JP, Keefe, RSE, Lowy, MT, Horrigan, JP, and Peykamian, MA. "Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy." April 15, 2012.
Uchida, H, Sakurai, H, Bies, RR, Stroup, S, Keefe, RSE, Suzuki, T, Tsuboi, T, Mimura, M, Pollock, BG, and Mamo, DC. "DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA." April 2012.
Colijn, MA, Barbato, M, Keefe, RS, Perkins, DO, Woods, SW, and Addington, J. "Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION." April 2012. Full Text
Keefe, RS, Buchanan, RW, Marder, SR, Schooler, NR, Dugar, A, Zivkov, M, and Stewart, M. "Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?." April 2012. Full Text
BI 1289.32 Phase II Clinical Trial awarded by Boehringer Ingelheim Pharmaceuticals, Inc. (Principal Investigator). 2017 to 2020
Auditory Perception and Emotion Recognition in Young People at Risk for Psychosis awarded by National Institutes of Health (Principal Investigator). 2016 to 2018
FAST- MAS Phase 2A awarded by National Institutes of Health (Co Investigator). 2013 to 2017
Specific Auditory Perception Impairment and Emotion Recognition in Schizophrenia awarded by National Institutes of Health (Principal Investigator). 2014 to 2017
FAST- MAS Administrative Task Year 3 awarded by National Institutes of Health (Co Investigator). 2014 to 2015
IPA - Richard Keefe awarded by Durham Veterans Affairs Medical Center (Research Associate). 2013 to 2014
IPA - Richard Keefe awarded by Veterans Administration Medical Center (Research Associate). 2012 to 2013
IPA - Richard Keefe awarded by Veterans Administration Medical Center (Fellow). 2010 to 2011
Neural Circuitry And Cognitive Function In Schizophrenia awarded by National Institutes of Health (Principal Investigator). 1995 to 2001
Neural Circuitry & Cognitive Function In Schizophrenia awarded by National Institutes of Health (Principal Investigator). 1995 to 1999